2012-10-06 19:02:47 - New Pharmaceuticals market report from Global Markets Direct: "Lupus Nephritis - Pipeline Review, H2 2012"

Global Markets Direct's, 'Lupus Nephritis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lupus Nephritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lupus Nephritis. Lupus Nephritis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated

disease.


Full Report Details at
- www.fastmr.com/prod/468386_lupus_nephritis_pipeline_review_h2_20 ..


Scope

* A snapshot of the global therapeutic scenario for Lupus Nephritis.
* A review of the Lupus Nephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Lupus Nephritis pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Lupus Nephritis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Lupus Nephritis pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Lupus Nephritis Overview
Therapeutics Development
An Overview of Pipeline Products for Lupus Nephritis
Lupus Nephritis Therapeutics under Development by Companies
Lupus Nephritis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Lupus Nephritis Therapeutics - Products under Development by Companies
Lupus Nephritis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Lupus Nephritis Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
Biogen Idec Inc.
Genentech, Inc.
Cephalon, Inc.
Human Genome Sciences, Inc.
Teva Pharmaceutical Industries Limited
Dynavax Technologies Corporation
Angelini Group
Deciphera Pharmaceuticals, LLC
NOXXON Pharma AG
Lupus Nephritis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
laquinimod sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIIB-023 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
belimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
abatacept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NOX-A12 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NOX-E36 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sirukumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IRS-954 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cyclosporine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mycophenolate Mofetil + Prednisolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituxan + Corticosteroids + Methylprednisolone + Mycophenolate mofetil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ocrelizumab + Mycophenolate Mofetil + Cyclophosphamide + Corticosteroids - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bindarit - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mycophenolate sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mesenchymal Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Abatacept + Cyclophosphamide + Azathioprine + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mycophenolate mofetil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Natura-Alpha - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AM-80 - Drug Profile

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468386&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.